Category Archives: Biotech

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, pricing, Regulatory, Strategy | Tagged , , | 1 Comment

Q&A: Nathan Tinker, New York Biotechnology Association

While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development. The New York Biotechnology Association is dedicated to the development and growth of New York State-based bioscience related industries and institutions. Moe Alsumidaie: How […]
Also posted in People | Tagged , , , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Also posted in Deals, Global, healthcare | Tagged , , , , , | Leave a comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Guest Blog, healthcare, leadership, Legal, Market Access, Strategy | Tagged , , , , , , , | 2 Comments

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in FDA, healthcare, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment
  • Categories

  • Meta